Table 4.

The effect of orally administered optimized resveratrol SEDDS (F19) compared with unprocessed resveratrol on body weight and serum glucose level in streptozotocin-induced diabetes mellitus in male albino rats

Group	Body weight (g)		Serum glucose level (mg/dL)
	Before treatment	After 4 weeks treatment	At the onset	At the end of experiment
N	195.12±3.9	219.9±8.81	95.5±3.6	106.3±3.4
DM	189.6±7.1	129.6±4.01*	296.8±9.1*	449.8±7.9*
CRV10	194.0±5.6	168.25±2.8*,**	282.8±7.6*	196.4±6.74*,**
FRV10	180.8±3.92	185.6±4.98*,**,***	266.35±5*,**	179.7±3.92*,**,***
CRV20	192.8±8.9	188.5±13.4**,***	272.3±4.4*,**	170.5±3.43*,**,***
FRV20	196.6±7.01	190.2±4.8**,***	267.6.±4.8*	172.3±4.15*,**,***

Notes: Values were expressed as mean ± standard error (n=10 per group). P-value is <0.05;

^*significant difference vs N group;

^**significant difference vs DM group; and

^***significant vs CRV10.

Abbreviations: N, nondiabetic control; DM, streptozotocin-induced diabetes; CRV10, DM treated with unprocessed resveratrol (10 mg/kg/day); FRV10, DM treated with optimal formula of resveratrol SEDDS (F19) (10 mg/kg/day); CRV20, DM treated with unprocessed resveratrol (20 mg/kg/day); FRV20, DM treated with optimal formula of resveratrol SEDDS (F19) (20 mg/kg/day); SEDDS, self-emulsifying drug delivery system.